Pharmaceutical Technology

APRIL 6, 2023

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. The new capabilities and IP will be incorporated under Ginkgo’s end-to-end AAV gene therapy development platform.

Engineer 130

Engineer Gene Therapy Gene Manufacturing 130

Pharmaceutical Technology

OCTOBER 26, 2022

The biotherapeutics market is rapidly growing, with 2021 seeing the highest-ever cell and gene therapy approval number. Gene therapy uses DNA to manipulate cells and correct defective genes, whereas cell therapy is the infusion or transplantation of cells into a patient.

Gene Therapy 130

Gene Therapy Gene Marketing Manufacturing 130

Pharmaceutical Technology

DECEMBER 14, 2022

Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.

Gene Therapy 130

Gene Therapy Gene Development Manufacturing 130

Pharmaceutical Technology

FEBRUARY 24, 2023

It will combine the extensive capabilities of AbbVie with the new adeno-associated virus (AAV) engineering platform and the manufacturing capability of Capsida for identifying and advancing three programmes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 130

Gene Therapy Gene Engineer Manufacturing 130

pharmaphorum

JUNE 15, 2021

When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. . The post Biogen’s ambitions in gene therapy hit by another failed pivotal trial appeared first on.

Gene Therapy 105

Gene Therapy Gene Trials Genetics 105

pharmaphorum

JANUARY 3, 2023

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for treatment of adult males with moderately severe to severe haemophilia B.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

pharmaphorum

OCTOBER 22, 2020

Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high-profile life sciences investors. Unlike a one-shot gene therapy, omaveloxolone would require continuous dosing to maintain its effects.

Gene Therapy 98

Gene Therapy Gene Life Science Engineer 98

XTalks

JANUARY 16, 2025

The RMAT pathway, tailored for therapies with promising potential, played a key role in accelerating bemdaneprocels progression. Bemdaneprocel is a cell therapy that uses pluripotent stem cells, cells capable of becoming any type of cell in the body.

Trials 104

Trials Clinical Trials Clinical Trials Gene Therapy 104

Pharmaceutical Technology

APRIL 14, 2023

The company can use its mammalian cell engineering expertise and capabilities to screen CAR T-cells, to discover and optimise next-generation therapeutic candidates for its partners. WARF and Ginkgo Bioworks also intend to partner on developing a pooled in vivo screening platform to further advance the discovery of new CAR therapies.

In-Vivo 264

In-Vivo Gene Therapy In-Vitro Engineer 264

Pharmaceutical Technology

APRIL 20, 2023

Circio aims to develop new circRNA medicines initially for cancer, then plans to expand rapidly into vaccines and gene therapy. CircAde is said to be the most advanced therapeutic concept, and leverages the company’s experience in oncolytic viruses to use engineered adenoviruses to deliver circRNA to cancer cells.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

XTalks

AUGUST 19, 2022

Bluebird bio’s gene therapy Zynteglo (betibeglogene autotemcel, beti-cel) has been awarded a much anticipated approval from the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with beta thalassemia who need regular blood transfusions. Bluebird has a total of three gene therapies in its pipeline.

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. This increases the expression of fetal haemoglobin.

Gene Therapy 264

Gene Therapy Drugs Gene Gene Editing 264

Pharmaceutical Technology

DECEMBER 8, 2022

It is created by taking T cells from the patient’s blood and then engineered in the laboratory to express chimeric antigen receptors. . Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Topic sponsors are not involved in the creation of editorial content. By Cytiva Thematic.

Licensing 305

Licensing Licensing Gene Therapy Gene 305

Pharmaceutical Technology

MARCH 29, 2023

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Development 245

Development Gene Therapy Gene Production 245

BioPharma Reporter

APRIL 11, 2023

Ginkgo acquires StrideBio's adeno-associated virus (AAV) capsid discovery and engineering platform assets and as well as gaining ownership of a preclinical asset.

Gene Therapy 98

Gene Therapy Gene Engineer Regulation 98

STAT News

JULY 11, 2022

Twenty-three years ago, the field of gene therapy was bursting with the promise of breakthrough treatments. Then it was almost instantly derailed by the death of an 18-year-old clinical trial volunteer named Jesse Gelsinger after he received a genetically engineered virus that had been developed to treat his rare liver condition.

Gene 111

Gene Gene Therapy Genetic Engineering Engineer 111

Pharmaceutical Technology

MARCH 8, 2023

The new technologies will also overcome the manufacturing bottlenecks in delivering advanced engineered cell products. Currently, there are six CAR T cell therapies that received approval from the US Food and Drug Administration (FDA) and approximately 560 programmes in ongoing studies.

Gene Therapy 244

Gene Therapy Manufacturing Gene Production 244

STAT News

AUGUST 18, 2022

The therapy, Zynteglo, is just the third gene therapy approved by the FDA, and the first to target a chronic blood disease. It uses an engineered virus to deliver a gene fix into the bone marrow of patients. Zynteglo will cost $2.8

Gene Therapy 98

Gene Therapy Gene FDA Approval Pharmacy 98

Pharmaceutical Technology

AUGUST 26, 2022

ElevateBio has signed a long-term strategic collaboration with the University of Pittsburgh, US, to establish a biomanufacturing centre for expediting cell and gene therapy development. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 162

Gene Therapy Gene Editing Gene Manufacturing 162

Scienmag

OCTOBER 19, 2020

New generation CRISPR technology lays foundation for therapeutics to treat a wide range of inherited ocular diseases Credit: Nature Biomedical Engineering Irvine, CA – October 19, 2020 – A breakthrough study, led by researchers from the University of California, Irvine, results in the restoration of retinal and visual functions of mice (..)

Gene Therapy 98

Gene Therapy Gene Engineer Research 98

Pharmaceutical Technology

OCTOBER 13, 2022

Inceptor Bio has partnered with cell engineering technology company Avectas to improve CAR-T cell therapies’ development and manufacturing to treat solid tumours. Under the collaboration deal, Inceptor Bio will use the Solupore technology from Avectas instead of electroporation for engineering T cells to yield a healthier T cell.

Development 147

Development Engineer Gene Therapy Gene 147

Pharmaceutical Technology

JUNE 29, 2022

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior. And it’s within the family – Novozymes!”.

Drugs 295

Drugs Gene Therapy Production Manufacturing 295

Roots Analysis

NOVEMBER 30, 2021

Bioassay – A Prerequisite for the Cell and Gene Therapy Development. Over the past few years, investigational new drug (IND) filings for cell and gene therapy product have significantly increased. Companies Offering Bioassay Services for Cell and Gene Therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

Advarra

AUGUST 8, 2023

Gene therapy research is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for gene therapy research. Defining the Boom in Gene Therapy Research The gene therapy field is experiencing explosive growth in today’s competitive research environment.

Gene Therapy 52

Gene Therapy Gene Research Genetics 52

Velocity Clinical Research

OCTOBER 3, 2024

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.”

Gene Therapy 52

Gene Therapy Gene Genetic Engineering Clinical Research 52

BioSpace

MAY 10, 2021

Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.

Gene Therapy 52

Gene Therapy Gene Engineer Genetics 52

BioTech 365

JANUARY 19, 2022

64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing 64x Bio Raises $55 Million Series A Financing to Advance Cell Line Engineering Platform for Gene Therapy Manufacturing Multibillion-dollar gene therapy market … Continue reading →

Gene Therapy 40

Gene Therapy Engineer Gene Manufacturing 40

BioPharma Reporter

SEPTEMBER 5, 2024

In one of the largest cell and gene therapy funding rounds this year, the US company Arsenal Biosciences has secured $325 million in a Series C round to bankroll T cell therapies engineered to take on solid tumors.

Engineer 52

Engineer Gene Therapy Development Gene 52

pharmaphorum

NOVEMBER 16, 2022

This is the case for the new generation of treatments known as advanced therapies, which encompasses cell and gene therapies, as well as tissue engineering. Of the innovations that have happened recently in pharma drug development, it is cell and gene therapy that have received the most attention.

Gene Therapy 131

Gene Therapy Gene Marketing Development 131

pharmaphorum

JANUARY 29, 2021

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences and Mammoth Biosciences – and the first drug therapies based on the technology are now in human testing for diseases like cancer. Macrae explains. “So

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

JUNE 12, 2023

Quell Therapeutics and AstraZeneca have entered a collaboration, exclusive option and licence deal for the development, manufacturing and commercialisation of engineered T-regulator (Treg) cell therapies for autoimmune diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Engineer 130

Engineer Gene Therapy Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 5, 2023

But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. More broadly however, several advancements are on the horizon for cell and gene therapies in 2023. AZ: Cell and gene therapies often come with a high price.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

Pharmaceutical Technology

JANUARY 4, 2023

Cell-engineering company MaxCyte has signed a strategic platform licence (SPL) with biotechnology company Catamaran Bio to support the chimeric antigen receptor (CAR)-NK cell therapy programmes. These CAR-NK cell therapies combine new functional attributes with the NK cells’ inherent cancer-fighting properties.

Engineer 130

Engineer Gene Therapy Gene Development 130

Advarra

JUNE 13, 2023

Research in gene therapies and genetically engineered drugs and vaccines are growing exponentially, and will only continue to become more popular. The accelerating gene therapy market is expected to grow globally by 16.6% between 2020-2027.

Gene Therapy 52

Gene Therapy Gene Research Genetic Engineering 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Several biotech companies and researchers are now exploring medical devices and gene therapies to address not just common forms of epilepsy, but also rare conditions such as Dravet Syndrome. Common gene therapies use vehicles such as adeno-associated vectors (AAVs), which cannot carry the required payload in this case, says Carney.

Research 264

Research Gene Gene Therapy Genomics 264

BioTech 365

OCTOBER 27, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ElevateBio cuts a deal for Life Edit, adding genome engineering tech to support gene therapy pipeline.ElevateBio cuts a deal for Life Edit, adding genome engineering tech to … Continue reading →

Gene Therapy 40

Gene Therapy Engineer Genome Genomics 40

Scienmag

JUNE 9, 2021

Credit: RCSI Scientists have developed polypeptide-based materials that act as effective vectors for delivering gene therapies. The first-of-its-kind platform enables the vectors to be adapted to suit the specific gene therapy cargo.

Gene Therapy 53

Gene Therapy Gene Scientist Medicine 53